Monday March 4, 2019 0 comments
The symposium, titled “DiaResQ: A Scientific Update,” presented the findings along with case studies from around the globe. The meeting was held at the Shangri La Hotel in Bangkok March 1-2.
According to the World Health Organization, diarrhea is the second-leading cause of death for children under five, with an estimated 1.7 billion cases of childhood diarrhea occurring each year.
More than 80% of the cases occur in developing countries, including those in Africa and South Asia. Standard of care is limited, and primarily focused on symptom relief and preventing dehydration.
PanTheryx said DiaResQ is a nutritional intervention that contains immune factors, micronutrients, and macronutrients that work with the body to address the underlying cause of diarrhea.
In clinical trials, DiaResQ resolved a majority of cases of pediatric diarrhea after one day of use. No serious adverse events attributable to DiaResQ have been reported in its clinical trials that have collectively enrolled over 1,000 children and adults, the company said.
“We’re excited to bring together our international partners and key opinion leaders to share the latest scientific substantiation of the safety and efficacy of DiaResQ,” said Scott Hyman, PanTheryx senior VP.
“It’s vital that we continue to make progress in addressing diarrhea, one of the leading causes of morbidity and mortality worldwide.
“We are working closely with clinicians and our partners to educate the medical community about the benefits of DiaResQ and ensure it’s available to everyone, especially children who are most at risk.”
Founded in 2007, PanTheryx is headquartered in Boulder and has production facilities in Phoenix and Ripon, CA.